Login
$MRNA
$213.17 -$2.10 (0.98%) After hours

$MRNA 8-K/A SEC Filings

Filed On Filing
01 Jun 2022 8-K/A: Departure/Election of Directors or Officers; Compensation

Updated Executive Retirement and Strategic Consulting Agreement

13 May 2022 8-K/A: Departure/Election of Directors or Officers; Compensation

Following up on discussions yesterday, this letter confirms the ending of your employment with Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigned, hereafter “Moderna” or the “Company...

09 Jun 2020 8-K/A: Departure/Election of Directors or Officers; Compensation

In connection with the appointment of David W. Meline as Chief Financial Officer of the Company, effective June 8, 2020, Mr. Meline was designated as the Company’s principal financial officer and principal accounting officer, succeeding ...

09 May 2019 8-K/A: Results of Operations and Financial Condition

Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support